- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.09. | ai3Bio, built from two biotechs, pursues a different path to an 'immune reset' | ||
| 29.09. | AstraZeneca invests $2B in Summit, gaining 'seat at the table' for PD-1/VEGF drug push | ||
| 28.09. | Kodiak skyrockets on positive study data for 2 eye drugs | ||
| 28.09. | An 'off-the-shelf' CAR-T therapy from Adicet shows promise against lupus | ||
| 28.09. | Merck, Daiichi end plans to seek speedy approval of lung cancer ADC | ||
| 28.09. | Kids shouldn't have to organize childhood around medicine | ||
| 28.09. | Breakthrough therapies still need builders | ||
| 25.09. | This week in charts: Novo's rise and fall and AI biotechs' big haul | ||
| 25.09. | Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer's data | ||
| 25.09. | RNAi drug specialist ADARx raises $446M IPO | ||
| 24.09. | Grail multicancer detection test wins FDA advisers' backing | ||
| 24.09. | FDA nominee Overton parries vaccine questions at Senate hearing | ||
| 24.09. | Merck reveals study success, and possible safety worries, for eye drug hopeful | ||
| 24.09. | Lilly's latest China drug deal; Immunovant's setback in lupus | ||
| 23.09. | Enveda, an AI drugmaker, banks $311M in venture funding | ||
| 23.09. | Roche, Ionis RNA drug scores in kidney disease study | ||
| 23.09. | 9 pharma leaders sound 'alarm bells' on biotech's decline in Europe | ||
| 22.09. | Amgen reports a Phase 3 win with Sjögren's drug candidate | ||
| 22.09. | Viking shares surge on updated obesity drug data | ||
| 22.09. | Celldex sinks as safety concerns cloud immune drug results | ||
| 22.09. | An orexin drug's 'proof-of-concept' in ADHD; Cue's 'unwarranted' share slide | ||
| 22.09. | A hidden tradeoff in Trump's drug pricing deals | ||
| 21.09. | Beacon eye gene therapy hits mark in late-stage study | ||
| 21.09. | Novo talks up drug launches in effort to win back investors | ||
| 21.09. | Telix buys ITM in bid to create a 'radiopharmaceutical powerhouse' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.